- Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001
-
As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure-activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).
- Nagy, Mark A.,Hilgraf, Robert,Mortensen, Deborah S.,Elsner, Jan,Norris, Stephen,Tikhe, Jayashree,Yoon, Won,Paisner, David,Delgado, Mercedes,Erdman, Paul,Haelewyn, Jason,Khambatta, Godrej,Xu, Li,Romanow, William J.,Condroski, Kevin,Bahmanyar, Sogole,McCarrick, Meg,Benish, Brent,Blease, Kate,Lebrun, Laurie,Moghaddam, Mehran F.,Apuy, Julius,Canan, Stacie S.,Bennett, Brydon L.,Satoh, Yoshitaka
-
p. 18193 - 18208
(2021/12/27)
-
- SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
-
Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
- -
-
Page/Page column 172
(2012/11/07)
-